Form 4: Director Equity Grant at Fate Therapeutics

Yuan Xu, a Director at Fate Therapeutics, received a grant of stock options.

Summary

• Yuan Xu, a Director at Fate Therapeutics (FATE), was granted stock options on June 12, 2026.
• The grant consists of 87,900 stock options with an exercise price of $2.06 per share.
• These options are exercisable starting June 12, 2026, and expire on June 12, 2036.
• The options vest and become exercisable on the earlier of June 12, 2027, or the date of the 2027 Annual Meeting of Stockholders, contingent upon continued service as a director.
• This grant is part of the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director as part of a compensation policy and does not indicate new financial performance or strategic shifts.

Positives

• Director Yuan Xu received a significant grant of 87,900 stock options, aligning their interests with the company's performance.
• The grant is part of a structured compensation policy for non-employee directors, indicating a formalized approach to director remuneration.
• The options have a long expiration date of June 12, 2036, providing a long-term incentive.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• The value of the stock options is subject to market fluctuations and the company's future stock performance.
• Vesting is contingent on continued service, meaning the options could be forfeited if the director leaves the board before the vesting date.

Future Outlook

The future outlook is tied to the vesting and potential exercise of the granted stock options, which are dependent on the company's stock performance and the director's continued service.

Management Comments

• This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
• The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and pharmaceutical sectors, serving to attract and retain experienced leadership while aligning their financial interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The transaction involves a grant of stock options from the issuer (Fate Therapeutics) to its director, Yuan Xu, which is a related party transaction governed by the company's compensation policy.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value. Dilution is minimal given the standard nature of such grants.
• Employees: This filing does not directly impact employees but reflects the company's compensation structure for its board.
• Management: The filing is a routine disclosure related to board compensation.

Next Steps

• The stock options will vest and become exercisable on the earlier of June 12, 2027, or the date of the Issuer's 2027 Annual Meeting of Stockholders, provided Yuan Xu continues to serve as a director.
• Yuan Xu may choose to exercise these options at any time after they become exercisable, up to the expiration date of June 12, 2036.

Key Dates

Keywords

stock options, director compensation, equity grant, Fate Therapeutics, FATE, SEC Form 4, insider trading, beneficial ownership